Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AF-130 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AF-130 capsule | EXPERIMENTAL | AF-130 oral capsules administered as a single dose or once daily for 7 days |
| AF-130 matching placebo capsule | PLACEBO_COMPARATOR | Oral placebo capsules to match AF-130 administered as a single dose or once daily for 7 days |
| Name | Type | Description |
|---|---|---|
| AF-130 | DRUG | AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days |
| Placebo comparator | DRUG | AF-130 matching placebo capsule |
Inclusion Criteria: * Healthy males * Age 18 to 55 years * Body mass index of 18.0 to 35.0 kg/m2 * Willing and able to communicate and participate in the whole study * Must provide written informed consent * Must agree to use an adequate method of contraception Exclusion Criteria: * Participation...
AF-130 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is currently in clinical development for research purposes only.
AF-130 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK on the New York Stock Exchange.
AF-130 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities.
AF-130 has one completed Phase 1 trial, NCT02652936, a pharmacokinetics study in healthy subjects. The trial enrolled 80 male participants in the United Kingdom and was placebo-controlled and double-blind.
No alternative names for AF-130 have been reported. It is identified solely by the code name AF-130 in clinical trial records.